Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
161Tb-SSO110
- Development stage
- Preclinical
- Lead developer
- Ariceum Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
161Tb-SSO110 is a therapeutic radiopharmaceutical consisting of the somatostatin receptor 2 (SSTR2) antagonist SSO110 (also known as DOTA-JR11 or satoreotide tetraxetan) labeled with the radioisotope terbium-161 (161Tb). Developed by Ariceum Therapeutics, it is designed to target SSTR2-expressing malignancies, including small cell lung cancer (SCLC) and neuroendocrine tumors. As an antagonist, SSO110 binds to a higher density of SSTR2 sites and exhibits longer tumor retention compared to traditional SSTR2 agonists like DOTATATE. The use of terbium-161 provides a combination of beta particles and short-range Auger and conversion electrons, which may enhance anti-tumor efficacy through increased linear energy transfer and localized radiation dose. Preclinical studies have demonstrated that 161Tb-SSO110 provides potent tumor growth inhibition in SCLC and pancreatic cancer models.
- Other names
- 161Tb-DOTA-JR11terbium-161 SSO110terbium161 SSO110terbium 161 SSO110terbium (161Tb) satoreotide tetraxetan
02
Targets
SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)
Beyond the preview
Go deeper on 161Tb-SSO110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 161Tb-SSO110.